Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Avalo Therapeutics, Inc. (AVTX : NSDQ)

• Company Description    Avalo Therapeutics Inc. is a clinical-stage precision medicine company which discovers, develops and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology and rare genetic diseases. Avalo Therapeutics Inc., formerly known as Cerecor, is based in WAYNE, Pa. Number of Employees: 23

• Price / Volume Information    Yesterday's Closing Price: $4.90 Daily Weekly Monthly 20 Day Moving Average: 79,178 shares Shares Outstanding: 10.83 (millions) Market Capitalization: $53.06 (millions) Beta: 0.77 52 Week High: $16.00 52 Week Low: $3.39 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.41% -3.35% 12 Week 11.11% -6.54% Year To Date -34.05% -38.24%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1500 Liberty Ridge Drive Suite 321 - Wayne,PA 19087 USA ph: 410-522-8707 fax: - ir@avalotx.com http://www.avalotx.com

• General Corporate Information    Officers Garry Neil - President and Chief Executive Officer; Chairman Christopher Sullivan - Chief Financial Officer June Almenoff - Director Mitchell Chan - Director Jonathan Goldman - Director Peer Information Avalo Therapeutics, Inc. (GSAC) Avalo Therapeutics, Inc. (CASI) Avalo Therapeutics, Inc. (ALCD.) Avalo Therapeutics, Inc. (OMNN) Avalo Therapeutics, Inc. (CGPI.) Avalo Therapeutics, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 05338F306 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 10.83 Most Recent Split Date: 12.00 (0.00:1) Beta: 0.77 Market Capitalization: $53.06 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.44 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.89 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.43 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 79.10% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -66.32% vs. Previous Quarter: -22.89% ROE 06/30/25 - - 03/31/25 - 111.00 12/31/24 - 1,157.52 ROA 06/30/25 - - 03/31/25 - 58.88 12/31/24 - 67.25 Current Ratio 06/30/25 - - 03/31/25 - 22.61 12/31/24 - 19.95 Quick Ratio 06/30/25 - - 03/31/25 - 22.61 12/31/24 - 19.96 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - 16,582.08 12/31/24 - -7,939.91 Book Value 06/30/25 - - 03/31/25 - 11.32 12/31/24 - 12.80 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©